Blueprint Medicines Corporation

Entasis Therapeutics, Inc.

Other

Astrazeneca Ab

Neil Bifulco

Chandrasekhar V Miduturu

Joseph L Kim

Natasja Brooijmans

Brian Lewis Hodous

Steven Mark Wenglowsky

Lucian V DiPietro

Douglas Wilson

Bolin Geng

Hoan Huynh

Thomas Francois Durand-Reville

Brendan Chen

Janelle Comita-Prevoir

Hui Xiong

Liang Zhao

Satenig Guler

Shanta Bist

Ye Wu

Daemian Dussault

Richard Vargas

Philip D Ramsden

Brian A Sherer

Allison Laura Choy

Helen Mcguire

Olga Quiroga

Helen McGuire

Lucian V Dipietro

Helen Maureen Mcguire

Daemian David Dussault

Thomas Durand-Reville

The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.

CDK2 inhibitors

This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.

Compounds and compositions useful for treating disorders related to NTRK

This disclosure relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants, such as compounds of Formula (I): 

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Inhibitors of the fibroblast growth factor receptor

This disclosure relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants, such as compounds of Formula I: 

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.

The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R, R, Rand Rare described herein.

&#x3b2;-lactamase inhibitor compounds

Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.

Beta-lactamase inhibitor compounds

Growing community of inventors

Sudbury, MA, United States of America

Neil Bifulco